GVK BIO steps into GLP tox with Vanta Bioscience acquisition

By Zachary Brennan contact

- Last updated on GMT

GVK BIO steps into GLP tox with Vanta Bioscience acquisition

Related tags: Biology

Indian CRO GVK BIO announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment CRO operating out of Chennai, India.

Vanta complies with OECD GLP, ISO, USFDA GLP (21 CFR Part 58 rev. 2009) regulatory guidelines, and offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries.

Manni Kantipudi, CEO, GVK BIO, said: “The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology​.”

The company’s sole facility is GLP and AAALAC accredited and armed with high-end equipment, and has infrastructure like “Individually ventilated Cages”​ and “Intelligent Building Management​” systems. The facility houses GLP-trained scientific personnel with experience and expertise in study design and execution of regulatory directed studies leading to IND filings.
Gerard Schwickerath, VP and General Manager, Vanta Bioscience, added: “Vanta Bioscience team is pleased that the world-class research GLP and AAALAC accredited organization will continue under the direction of GVK BIO. We are delighted to transition into an organization that can expand our offerings and provide further opportunities to our clients and staff​.”

Dorothy Paul, a spokeswoman for GVK, told us: "There is a demand for GLP toxicology in India. The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology​."

Prior Issues

The acquisition comes a little more than a month after the EMA announced​ it would open an investigation into allegations that GVK falsified electrocardiograms in eight clinical trials.

GVK had until early October to respond to EMA requests on the root cause of the issues affecting the Hyderabad, India site.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars